
"Shareholders should be careful about Pfizer's bid," Borg told reporters.

"There is a significant development of new drugs in AstraZeneca. If they (Pfizer) start to divide up the company and put it together with different parts of Pfizer, there is a danger that the process will be complicated."

Borg also said Pfizer's shareholders should ask themselves whether they should support the company's management in its aggressive pursuit of AstraZeneca.

This discussion is now closed. We welcome comments on our articles for a limited period after their publication.
